Оцените презентацию от 1 до 5 баллов!
Тип файла:
ppt / pptx (powerpoint)
Всего слайдов:
33 слайда
Для класса:
1,2,3,4,5,6,7,8,9,10,11
Размер файла:
3.81 MB
Просмотров:
48
Скачиваний:
0
Автор:
неизвестен
Слайды и текст к этой презентации:
№1 слайд![](/documents_6/dd16c1bee56da347e649e9aaab268d48/img0.jpg)
№2 слайд![The global burden of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img1.jpg)
Содержание слайда: The global burden of postpartum haemorrhage
The global burden of postpartum haemorrhage
№3 слайд![What is postpartum](/documents_6/dd16c1bee56da347e649e9aaab268d48/img2.jpg)
Содержание слайда: What is postpartum haemorrhage?
Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide.
Postpartum haemorrhage (PPH) is commonly defined as a blood loss of 500 ml or more within 24 hours after birth. It affects about 5% of all women giving birth around the world.
Globally, nearly one quarter of all maternal deaths are associated with PPH. In most low-income countries, it is the main cause of maternal mortality.
№4 слайд![New findings on uterotonics](/documents_6/dd16c1bee56da347e649e9aaab268d48/img3.jpg)
Содержание слайда: New findings on uterotonics for PPH prevention
2. Uterotonics for PPH prevention
№5 слайд![New findings on uterotonics](/documents_6/dd16c1bee56da347e649e9aaab268d48/img4.jpg)
Содержание слайда: New findings on uterotonics for PPH prevention
2. Uterotonics for PPH prevention
№6 слайд![A systematic approach The](/documents_6/dd16c1bee56da347e649e9aaab268d48/img5.jpg)
Содержание слайда: A systematic approach
The recommendations were updated according to the standards of the WHO handbook on guideline development
№7 слайд![GDG formulates the](/documents_6/dd16c1bee56da347e649e9aaab268d48/img6.jpg)
Содержание слайда: GDG formulates the recommendations
The Guideline Development Group (GDG) convened in September & October 2018
The GDG comprised 18 external experts and relevant stakeholders with expertise in research, guideline development, policy and programmes on PPH prevention and treatment.
№8 слайд![What works? Efficacy and](/documents_6/dd16c1bee56da347e649e9aaab268d48/img7.jpg)
Содержание слайда: What works?
Efficacy and safety of uterotonics for PPH prevention
uterotonic options
vs
placebo or no treatment
4. What are the updated WHO recommendations?
№9 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img8.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№10 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img9.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№11 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img10.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№12 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img11.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№13 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img12.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№14 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img13.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
№15 слайд![Recommendation . The use of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img14.jpg)
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births.
To effectively prevent PPH, only one of the following uterotonics should be used:
Oxytocin
Carbetocin
Misoprostol
Ergometrine/methylergometrine
Oxytocin and ergometrine fixed-dose combination
Injectable prostaglandins
№16 слайд![How do we compare uterotonics](/documents_6/dd16c1bee56da347e649e9aaab268d48/img15.jpg)
Содержание слайда: How do we compare uterotonics to one another?
4. Which one: identifying a uterotonic of choice
№17 слайд![](/documents_6/dd16c1bee56da347e649e9aaab268d48/img16.jpg)
№18 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img17.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№19 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img18.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№20 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img19.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№21 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img20.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№22 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img21.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№23 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img22.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№24 слайд![. Which one Summary of](/documents_6/dd16c1bee56da347e649e9aaab268d48/img23.jpg)
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№25 слайд![Recommendation . In settings](/documents_6/dd16c1bee56da347e649e9aaab268d48/img24.jpg)
Содержание слайда: Recommendation 2. In settings where multiple uterotonic options are available, oxytocin (10 IU, IM/IV) is the recommended uterotonic agent for the prevention of PPH for all births.
Vaginal birth or caesarean section
Skilled health personnel are required
№26 слайд![Recommendation . In settings](/documents_6/dd16c1bee56da347e649e9aaab268d48/img25.jpg)
Содержание слайда: Recommendation 3. In settings where oxytocin is unavailable (or its quality cannot be guaranteed), the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended.
Vaginal birth or caesarean section
Skilled health personnel are required
№27 слайд![Recommendation . In settings](/documents_6/dd16c1bee56da347e649e9aaab268d48/img26.jpg)
Содержание слайда: Recommendation 4. In settings where skilled health personnel are not present to administer injectable uterotonics, the administration of misoprostol (either 400 µg or 600 µg PO) by community health care workers and lay health workers is recommended for the prevention of PPH.
If skilled health personnel are not present or have not been trained to administer injectable uterotonics, oral misoprostol is preferred
№28 слайд![. What s new wider scope,](/documents_6/dd16c1bee56da347e649e9aaab268d48/img27.jpg)
Содержание слайда: 5. What’s new: wider scope, more evidence
5. What’s new: wider scope, more evidence
№29 слайд![. So what s new More](/documents_6/dd16c1bee56da347e649e9aaab268d48/img28.jpg)
Содержание слайда: 5. So what’s new: More recommendations, greater specificity
5. So what’s new: More recommendations, greater specificity
№30 слайд![. implementing the updated](/documents_6/dd16c1bee56da347e649e9aaab268d48/img29.jpg)
Содержание слайда: 6. implementing the updated WHO recommendations
6. implementing the updated WHO recommendations
№31 слайд![Implementation considerations](/documents_6/dd16c1bee56da347e649e9aaab268d48/img30.jpg)
Содержание слайда: Implementation considerations
Update clinical guidance
Develop or revise existing clinical guidelines, protocols or job aids
№32 слайд![Implementation considerations](/documents_6/dd16c1bee56da347e649e9aaab268d48/img31.jpg)
Содержание слайда: Implementation considerations
Quality-certified uterotonics
Regulatory, procurement and logistics processes that work
№33 слайд![Contact us](/documents_6/dd16c1bee56da347e649e9aaab268d48/img32.jpg)
Содержание слайда: Contact us